Recent advances in vaccine delivery

Journal of Applied Pharmaceutical Science

Volumn 1, Issue 1, 2011, Pages 30-37

  Soni, J Khyati ^a   Patel, P Rakesh ^a   Asari, M Vaishnavi ^a   Prajapati, G Bhupendra ^a  

^a GANPAT UNIVERSITY   (India)

Author keywords

Drug delivery; Intradermal; Intranasal; Needle free delivery; Transcutaneous; Vaccine

Indexed keywords

EID: 84875828479     PISSN: None     EISSN: 22313354     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Belshe RB., Newman FK., Wilkins K. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine. 2007; 25(37-38):6755-6763.
2. Bernard KW., Mallonee J., Wright JC. Preexposure immunization with intradermal human diploid cell rabies vaccine, Risks and benefits of primary and booster vaccination. The Journal of the American Medi Asso. 2005; 257(8): 1059-1063.
3. Booy R., Weber F., Saville M. Immunogenicity of a novel influenza vaccine delivered by intradermal microinjection in over 60 year-olds. Options for the control of Influenza VI. Toronto, Canada, June 2007
4. Chabri F., Bouris K., Jones T. Microfabricated silicon microneedles for nonviral cutaneous gene delivery. The British Journal of Dermato. 2004 ;150(5): 869-877.
5. Chen X. Dry-coated microprojection patches for targeted delivery of immunotherapeutics to the skin. J Controlled Release.2009;139( 3): 212-220.
6. Cui Z., Baizer L., Mumper RJ. Intradermal immunization with novel plasmid DNAcoated nanoparticles via a needle-free injection device. J of Biotechnology.2003; 102(2): 105-115
7. Gill HS., Prausnitz MR., Coating formulations for microneedles. Pharma Research.2007; 24(7): 1369-1380.
8. Glenn G., Kenney RT. Transcutaneous immunization. In: Levine MM., Kaper JB., Rappuoli R., Liu MA.,ed. New Generation Vaccines, Marcel Dekker, New York 2004, 401-412.
9. Gupta PN., Mishra V., Rawat A., Dubey P., Mahor S., Jain S., Chatterji DP., Vyas SP., Non-invasive vaccine delivery in transfersomes, niosomes and liposomes: a comparative study. Int. J. Pharm.2005; 293(1-2): 73-82.
10. Gutierrez MJ., Stout RR., Williamson D. A springpowered device for subcutaneous, intramuscular and intradermal injections using an auto-disable syringe. Drug Delivery Techno.2007; 7(2):3-40.
11. Hatsukami DK., Rennard S., Jorenby D., Fiore M., Koopmeiners J., de Vos A., Horwith G., Pentel PR. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clinical Pharmacology & Therapeutics. 2005; 78 (5):456-467.
12. Hines JF. Prospects for human papillomavirus vaccine development: emerging HPV vaccines. Curr Opin Obstet Gynecol.1998; 10(1): 15-19.
13. Huang J. Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge. Hum Vaccines. 2007; 3(3) 90-93
14. Jackson LA., Austin g., Chen rt., Stoutr., DeStefano F., Gorse GJ., Newman FK., Yu O., Weniger BG. Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine. 2001; 19(32) 4703-4709.
15. Jain S., Jain P., Umamaheshwari S., Jain NK. Transfersomes-a novel vesicular carrier for enhanced transdermal delivery: development, characterization, and performance evaluation. Drug Dev Ind Pharm.2003; 29(9) 1013-1026.
16. Kane A., Lloyd J., Zaffran M., Simonsen L., Kane M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bullet of the World Health Organ.2000; 77(10): 801-807.
17. Kim D., Elizaga M., Duerr A. HIV vaccine efficacy trials: towards the future of HIV prevention. Infect Dis Clin North Am. 2007; 21 (1): 201-217
18. Kommareddy S., Tiwari SB., Amiji MM., Longcirculating polymeric nanovectors for tumor-selective gene delivery. Technol Cancer Res Treat. 2005;4(6): 615-625.
19. Laurent PE., Bonnet S., Alchas P. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine.2007; 25(52): 8833-8842.
20. Lee JW., Park JH., Prausnitz MR. Dissolving microneedles for transdermal drug delivery. J Biomaterials.2008; 29(13): 2113-2124.
21. Levine MM., Campbell JD. Mucosal immunization and needle-free injection devices. In: Levine MM., Kaper JB., Rappuoli R., Liu MA., Good MF.,ed. New Generation Vaccines, Marcel Dekker, New York, 2004, 393-399.
22. Lowy DR., Schiller JT., Papillomaviruses and cervical cancer: pathogenesis and vaccine development. J Natl Cancer Inst Monogr.1998; 23: 27-30.
23. Marques R., Williams A., Eksmond U., Wullaert A., Killeen N., Pasparakis M., Kioussis D., Kassiotis G. Generalized immune activation as a direct result of activated CD4+ T cell killing. J Biology.2009; 8 (10): 93.
24. Maurer P., Jennings GT., Willers J., Rohner F., Lindman Y., Roubicek K., Renner WA., Muller P., Bachmann MF. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. European Journal of Immunology.2005; 35 (7): 2031-2040.
25. Mascioni A., Bentley BE., Camarda R. Structural basis for the immunogenic properties of the meningococcal vaccine candidate. J. Biol. Chem.2008; 284 (13): 8738-8746.
26. McAllister DV., Wang PM., Davis SP. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies. Proc Natl Acad Sci USA.2003; 100( 24): 13755-13760.
27. Mishra D., Mishra PK., Dubey V., Nahar M., Dabadghao S., Jain NK. Systemic and mucosal immune response induced by transcutaneous immunization using Hepatitis B surface antigenloaded modified liposomes. Eur. J. Pharm. Sci.2008; 33(4-5) 424-433.
28. Mutsch M., Zhou W., Rhodes P. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med.2004;350(9):896-903.
29. Park JH., Allen MG., Prausnitz MR. Biodegradable polymer microneedles: fabrication, mechanics and transdermal drug delivery. J Controlled Release.2005; 104( 1): 51-66.
30. Pearton M., Allender C., Brain K. Gene delivery to the epidermal cells of human skin explants using microfabricated microneedles and hydrogel formulations. Pharma Research.2008; 25( 2): 407-416.
31. Shaw M., Sullivan T., Zielinski W. Unit-dose aseptic packaging of nasal drugs.Inhalat.2008;2: 8-11.
32. Shahiwala A., Vyas TK., Amiji MM. Nanocarriers for Systemic and Mucosal Vaccine Delivery. Recent Pat Drug Deliv Formul.2007;1(1):1-9.
33. Simonsen L., Kane A., Lloyd J., Zaffran M., Kane M. Unsafe injections in the developing world and transmission of blood borne pathogens. Bullet of the World Health Organ.1999; 77(10): 789-800.
34. Stanfield JP., Bracken PM., Waddell KM., Gall D. Diphtheria-tetanus-pertussis immunization by intradermal jet injection. British Medi Journal.1972;2(5807):197-199
35. Stern AM, Markel H. The history of vaccines and immunization: familiar patterns, new challenges. Health Aff. 2005; 24 (3): 611-621.
36. Steinglass R., Boyd D., Grabowsky M., Laghari AG., Qavi A., Evans P.Safety, effectiveness and ease of use of a non-reusable syringe in a developing country immunization programme. Bullet of the World Health Organ.2005; 73 (1): 57-63.
37. Suman JD. Nasal drug delivery. Exp Opin Biolog Therapy. 2003;3(3):519-523.
38. Tafaghodi M., Jaafari MR., Sajadi TSA. Nasal immunization studies using liposomes loaded with tetanus toxoid and CpG-ODN. Eur J Pharm Biopharm. 2006; 64(2): 138-145.
39. Tindle R. Human papillomavirus vaccines for cervical cancer. Curr Opi Immunol.1996; 8;(5): 643-650.
40. Tomasi M., Dertzbaugh MT., Hearn T., Hunter RL., Elson CO. Strong mucosal adjuvanticity of cholera toxin within lipid particles of a new multiple emulsion delivery system for oral immunization. Eur J Immunol. 1997; 27(10): 2720-2725.
41. Vrisekoop N., Mandl J N., Germain RN. Life and death as a T lymphocyte: from immune protection to HIV pathogenesis. J Biology. 2009; 8 (10): 91.
42. Vu D., Welsch J., Zuno-Mitchell P., Dela Cruz J., Granoff D. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis. 2006; 193 (6): 821-828.
43. Watkins DI. Basic HIV Vaccine Development. Top HIV Med.2008; 16 (1): 7-8.
44. Watkins DI. The hope for an HIV vaccine based on induction of CD8+ T lymphocytes, Mem. Inst. Oswaldo Cruz. 2008; 103 (2): 119-129
45. Weniger BG., Papania MJ. Alternative vaccine delivery methods, In: Plotkin SA, Orenstein WA, Offit PA.,ed. Vaccines. 5th ed, Amsterdam, Netherlands, 2008,1357-1392.
46. Williams J., Fox L., Christensen C. Hepatitis A vaccine administration: comparison between jet-injector and needle injection. Vaccine.2000;18(18):1939-1943
47. Wolfe R., Sharp L. Anti-vaccinationists past and present. BMJ.2002; 325(7361):430-432. www.seruminstitute.com
48. Zho F., Neutra, MR. Antigen delivery to mucosaassociated lymphoid tissues using liposomes as a carrier. Biosci Rep. 2002; 22(2): 355-369.